Figure 3.
PFS by number of prior therapies and cytogenetic subgroups (ITT population randomized to ibrutinib). (A) Analysis by number of prior therapies. (B) Analysis by del(17)(p13.1) and del(11)(q22.3). (C) Analysis by complex karyotype.
PFS by number of prior therapies and cytogenetic subgroups (ITT population randomized to ibrutinib). (A) Analysis by number of prior therapies. (B) Analysis by del(17)(p13.1) and del(11)(q22.3). (C) Analysis by complex karyotype.